A new criterion by which to discriminate between patients with moderate allergic rhinitis and patients with severe allergic rhinitis based on the Allergic Rhinitis and its Impact on Asthma severity items Antonio Valero, MD, PhD, Montse Ferrer, MD, PhD, Joaquín Sastre, MD, PhD, Ana M. Navarro, MD, PhD, Laura Monclús, MD, Enrique Martí-Guadaño, MD, PhD, Michael Herdman, MSc, Ignacio Dávila, MD, PhD, Alfonso del Cuvillo, MD, PhD, Carlos Colás, MD, PhD, Eva Baró, BSc, Ignacio Antépara, MD, PhD, Jordi Alonso, MD, PhD, Joaquim Mullol, MD, PhD Journal of Allergy and Clinical Immunology Volume 120, Issue 2, Pages 359-365 (August 2007) DOI: 10.1016/j.jaci.2007.04.006 Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 1 Distribution of patients with moderate/severe allergic rhinitis (N = 141) on symptoms (TSS4) and HRQL (RQLQ global score, SF-12 MCS and PCS). Journal of Allergy and Clinical Immunology 2007 120, 359-365DOI: (10.1016/j.jaci.2007.04.006) Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 2 Distribution of patients when defined by the number of affected ARIA items in severe (4 impaired items) and moderate (those with 1, 2, or 3 impaired items). Mean ± SD and P value of t test comparing moderate and severe groups were as follows: for TSS4, symptom score 7.3 ± 2.2 vs 8.7 ± 2.0 (P < .0004); for RQLQ, global score 2.4 ± 1.0 vs 3.5 ± 0.9 (P < .0001); for SF-12 PCS, score 49.8 ± 7.9 vs 40.5 ± 9.3 (P < .0001); and for SF-12 MCS, score 47.9 ± 9.9 vs 45.6 ± 11.0 (NS). Journal of Allergy and Clinical Immunology 2007 120, 359-365DOI: (10.1016/j.jaci.2007.04.006) Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions